Sanofi is jet­ti­son­ing its in­fec­tious dis­ease unit to Evotec — hand­ing over cash, staff and a pipeline

Sanofi is spin­ning out its in­fec­tious dis­ease re­search unit to Evotec, the Ger­man con­tract de­vel­op­ment or­ga­ni­za­tion known for its deal savvi­ness. And the Paris-based phar­ma gi­ant $SNY — suf­fer­ing from a long drought that has blight­ed its in­ter­nal R&D ops — is hand­ing over €60 mil­lion (around $74 mil­lion) up­front for the op­er­a­tion along with con­tin­ued fi­nanc­ing, 10 ex­per­i­men­tal in­fec­tious dis­ease projects and 100 of its staffers to get it all go­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER